NCT00100243

Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy

Phase 2 Study of Abarelix in Androgen-Independent Prostate Cancer Progressing After Agonist Therapy

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 22 (planned)
• Sponsor: PRAECIS Pharmaceuticals Inc. · Industry
• Sex: Male
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a Phase 2, open-label study in subjects with androgen-independent prostate cancer who have progressed following treatment with an LHRH agonist. Up to 22 subjects will be enrolled. Enrollment will be monitored to ensure that not all subjects are enrolled based on rising prostate specific antigen (PSA) criterion only. Subjects will be treated with abarelix (Plenaxis) 100 mg intramuscularly (IM) every 2 weeks for 12 weeks (total dose of 600 mg).

Conditions

• Prostate Cancer

Interventions

Type	Name	Description
DRUG	Plenaxis

Timeline

• Start date: 2004-05-01
• Completion: 2005-09-01
• First posted: 2004-12-28
• Last updated: 2006-09-19

Locations

7 sites across 1 country: United States